Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

The SET protein promotes androgen production in testicular Leydig cells

View through CrossRef
SummaryApproximately 40% of middle‐aged men exhibit symptoms of late‐onset hypogonadism (LOH). However, the mechanism of androgen deficiency is still currently unclear. As shown in our previous studies, the SET protein is expressed in testicular Leydig cells and ovarian granule cells. This study was designed to investigate the effect of the SET protein on androgen production in Leydig cells. The AdCMV/SET and AdH1siRNA/SET adenoviruses were individually transduced into a cultured mouse Leydig cell line (mLTC‐1) with or without human chorionic gonadotropin (HCG) stimulation in vitro. The primary mouse Leydig cells were used to confirm the main data from mLTC‐1 cells. The SET protein was expressed in the cytoplasm and nucleus of mLTC‐1 cells. Testosterone production was significantly increased in mLTC‐1 cells overexpressing the SET protein compared with the control group (p < 0.05), whereas testosterone production was significantly decreased in the SET knockdown mLTC‐1 cells (p < 0.05). Consistent with the testosterone levels, the expression levels of the steroidogenic acute regulatory (StAR) and cytochrome P450c17α‐hydroxylase (CYP17a1) mRNAs and proteins synchronously changed according to the expression level of the SET protein. Interestingly, the expression of the SET protein was significantly increased in the mLTC‐1 cells stimulated with 0.04 and 0.1 U/mL hCG. In the mLTC‐1 cells transfected with AdH1siRNA/SET and concurrently stimulated with 0.1 U/mL hCG, both testosterone production and StAR expression were significantly lower than in the cells without SET knockdown (p < 0.05). In conclusion, the SET protein participates in regulating testosterone production by increasing the expression of StAR and CYP17a1, and it may be a downstream factor of the classic luteinizing hormone (LH)/luteinizing hormone receptor (LHR) signaling pathway. This study improves our understanding of the intracellular mechanism of testicular steroidogenesis and the pathophysiological mechanism of LOH in the aging male.
Title: The SET protein promotes androgen production in testicular Leydig cells
Description:
SummaryApproximately 40% of middle‐aged men exhibit symptoms of late‐onset hypogonadism (LOH).
However, the mechanism of androgen deficiency is still currently unclear.
As shown in our previous studies, the SET protein is expressed in testicular Leydig cells and ovarian granule cells.
This study was designed to investigate the effect of the SET protein on androgen production in Leydig cells.
The AdCMV/SET and AdH1siRNA/SET adenoviruses were individually transduced into a cultured mouse Leydig cell line (mLTC‐1) with or without human chorionic gonadotropin (HCG) stimulation in vitro.
The primary mouse Leydig cells were used to confirm the main data from mLTC‐1 cells.
The SET protein was expressed in the cytoplasm and nucleus of mLTC‐1 cells.
Testosterone production was significantly increased in mLTC‐1 cells overexpressing the SET protein compared with the control group (p < 0.
05), whereas testosterone production was significantly decreased in the SET knockdown mLTC‐1 cells (p < 0.
05).
Consistent with the testosterone levels, the expression levels of the steroidogenic acute regulatory (StAR) and cytochrome P450c17α‐hydroxylase (CYP17a1) mRNAs and proteins synchronously changed according to the expression level of the SET protein.
Interestingly, the expression of the SET protein was significantly increased in the mLTC‐1 cells stimulated with 0.
04 and 0.
1 U/mL hCG.
In the mLTC‐1 cells transfected with AdH1siRNA/SET and concurrently stimulated with 0.
1 U/mL hCG, both testosterone production and StAR expression were significantly lower than in the cells without SET knockdown (p < 0.
05).
In conclusion, the SET protein participates in regulating testosterone production by increasing the expression of StAR and CYP17a1, and it may be a downstream factor of the classic luteinizing hormone (LH)/luteinizing hormone receptor (LHR) signaling pathway.
This study improves our understanding of the intracellular mechanism of testicular steroidogenesis and the pathophysiological mechanism of LOH in the aging male.

Related Results

Abstract A6: Androgen receptor-mediated transcription is reprogrammed after hormone depletion
Abstract A6: Androgen receptor-mediated transcription is reprogrammed after hormone depletion
Abstract Androgen receptor (AR) is a ligand-induced transcription factor, which binds to thousands of genomic loci and activates a cell-type specific gene expression...
Prepubertal Buffalo (Bubalus bubalis) Leydig Cells: Isolation, Culture and Characterization
Prepubertal Buffalo (Bubalus bubalis) Leydig Cells: Isolation, Culture and Characterization
Water buffalo (Bubalus bubalis) is an economically important livestock species in India. Male buffaloes display delayed sexual maturity as compared to the bulls (Bos taurus). Serum...
Prenatal DEHP exposure induces lifelong testicular toxicity by continuously interfering with steroidogenic gene expression
Prenatal DEHP exposure induces lifelong testicular toxicity by continuously interfering with steroidogenic gene expression
Abstract Epidemiologic studiessuggested the association between prenatal Di-(2-ethylhexyl) phthalate (DEHP) exposure and disorders of sex development (DSD), adult male diso...
Data from Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for <i>In vitro</i> and <i>In vivo</i> Activity
Data from Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for <i>In vitro</i> and <i>In vivo</i> Activity
<div>Abstract<p>Leydig cell tumors are usually benign tumors of the male gonad. However, if the tumor is malignant, no effective treatments are currently available. Ley...
Abstract 354: Monitor androgen blockade therapy with functional androgen receptor reporting system
Abstract 354: Monitor androgen blockade therapy with functional androgen receptor reporting system
Abstract Hormonal manipulation remains the first line treatment for advanced prostate cancer. It includes surgical and medical means of androgen deprivation and andr...

Back to Top